Saturday 17 October 2026
Export AARD’s income statement to Excel — free account
Aardvark Therapeutics, Inc.
AARD Healthcare Biotechnology
In the quarter to June 2026, EPS was flat and free cash flow fell 77.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.78
0.08
−2.07%
Follow AARD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(111.38%) | (221.55%) | (58.79%) | (66.02%) | |
| (67.85%) | (59.16%) | (54.67%) | (61.06%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (4,986.18%) | |
Return on Tangible Assets |
(41.17%) | (56.83%) | (85.23%) | (94.10%) | |
Free Cash Flow per Share |
(2.08) | (2.77) | (2.83) | (3.18) | |
Free Cash Flow |
(45.19) | (54.27) | (61.65) | (69.41) | |
Capital Expenditures |
(0.11) | (0.10) | — | — | |
| Other line items | |||||
Cash ROIC |
(18.17%) | (25.05%) | (34.60%) | (46.69%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.92 | 0.94 | 0.88 | 0.99 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.09 | 0.08 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.08) | (2.76) | (2.83) | (3.18) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates